Endogenous peptide and active subfragments thereof

Details Endogenous peptide and active subfragments thereof Endogenous peptide and active subfragments thereof

2004-07-05

2010-02-16

Haddad, Maher M (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C514S002600, C530S324000, C530S325000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000

Reexamination Certificate

active

07662388

ABSTRACT:
The present invention relates to a substantially pure biologically active consecutive anti-angiogenic polypeptide comprising the central region of human Histidine Rich Glycoprotein (HRGP). Said polypeptide is shown to comprise a potential endogenous, naturally occurring subfragment of human HRGP, comprising similar anti-angiogenic activities as the mature protein. The present invention also relates to one or more new biologically active subfragments of human HRGP, derived from said central region. Said subfragments are all characterized by having anti-angiogenic activity. One of the active subfragments is referred to as Pep2. Enscoped by the present invention are also anti-angiogenic subfragments derived from Pep2, one of them comprising a newly identified presently minimal functional entity.

REFERENCES:
patent: 7205392 (2007-04-01), Olsson et al.
patent: 7294515 (2007-11-01), Hutchens et al.
patent: 7563765 (2009-07-01), Olsson et al.
patent: 2001/0041670 (2001-11-01), Simantov et al.
patent: 2005/0042201 (2005-02-01), Olsson et al.
patent: WO02/064621 (2002-08-01), None
patent: WO02/076486 (2002-10-01), None
patent: WO03/077872 (2003-09-01), None
J.C. Juarez, et al. “Histidine-proline-rich Glycoprotein has potent antiangiogenic activity mediated through the histidine-proline domain”Cancer Researchvol. 62 (Sep. 15, 2002), pp. 5344-5350.
R. Simantov, et al. “Histidine-rich glycoprotein inhibits the antiagiogenic effect of thrombospondin-1”The Journal of Clinical Investigation(Jan. 2001) vol. 107 (1), pp. 45-52.
A. Olsson, et al. “A fragment of histidine-rich glycoprotein is a potent inhibitor of tumor vascularization”Cancer Researchvol. 64 (2004) pp. 599-605.
Hulett M.D., et al. “Murine histidide-rich glycoprotein: Cloning, characterization and cellular origin”Immunology and Cell Biology(2000) 78, pp. 280-287.
D. J. Borza, et al. “Domain structure and conformation of histidine-roline-rich glycoprotein”Biochemistry(1996) vol. 35, pp. 1925-1934.
T. Kolde, et al. “Amino Acid Sequence of Human Histidine-Rich Glycoprotein Derived from the Nucleotide Sequence of its cDNA”Biochemistryvol. 25 (1986), pp. 2220-2225.
H.K. Lunen, et al. “Interaction of Heparin with Histidine-rich Glycoprotein”Annals New York Academy of Sciencesvol. 556 (1985), pp. 181-185.
Borza and Morgan, “Histidine-Proline-rich Glycoprotein as a Plasma pH Sensor,”J. Biol. Chem., 1998, 273(10):5493-5499.
Borza and Morgan, “Acceleration of Plasminogen Activation by Tissue Plasminogen Activator on Surface-bound Histidine-proline-rich Glycoprotein,”J. Biol. Chem., 1997, 272(8):5718-5726.
Brown and Parish, “Histidine-Rich Glycoprotein and Platelet Factor 4 Mask Heparan Sulfate Proteoglycans Recognized by Acidic and Basic Fibroblast Growth Factor,”Biochem., 1994, 33:13918-13927.
Carmeliet and Jain, “Angiogenesis in cancer and other diseases,”Nature, 2000, 407:249-257.
Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,”Nature Med., 1995, 1(1):27-31.
Gorgani et al., “Histidine-Rich Glycoprotein Binds to Human IgG and Clq and Inhibits the Formation of Insoluble Immune Complexes,”Biochem., 1997, 36:6653-6662.
Gorgani et al., “Histidine-Rich Glycoprotein Binds to DNA and FcγRI and Potentiates the Ingestion of Apoptotic Cells by Macrophages,”J. Immunol., 2002, 169:4745-4751.
Gura, “Cancer Models: Systems for Identifying New Drugs Are Often Faulty,”Science, 1997, 278:1041-1042.
Hawighorst et al., “Activation of the Tie2 Receptor by Angiopoietin-1 Enhances Tumor Vessel Maturation and Impairs Squamous Cell Carcinoma Growth,”Am. J. Pathol., 2002, 160(4):1381-1392.
Kerbel, “Tumor angiogenesis: past, present and the near future,”Carcinogenesis, 2000, 21(3):505-515.
Koide et al., “The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III,”FEBS, 1986, 194(2):242-244.
Kluszynski et al., “Zinc as a Cofactor for Heparin Neutralization by Histidine-rich Glycoprotein,”J. Biol. Chem., 1997, 272(21):13541-13547.
Lamb-Wharton and Morgan, “Induction of T-Lymphocyte Adhesion by Histidine-Proline-Rich Glycoprotein and Concanavalin A,”Cell. Immunol., 1993, 152:544-555.
Lijnen et al., “Heparain Binding Properties of Human Histidine-rich Glycoprotein. Mechanism and Role in the Neutralization of Heparin in Plasma,”J. Biol. Chem., 1983, 258(6):3803-3808.
Olsen et al., “Histidine-rich glycoprotein binding to T-cell lines and its effect on T-cell substratum adhesion is strongly potentiated by zinc,”Immunology, 1996, 88:198-206.
Peterson et al., “Histidine-rich Glycoprotein Modulation of the Anticoagulant Activity of Heparin,”J. Biol. Chem., 1987, 262(16):7567-7574.
Simon et al., “Peptoids: a modular approach to drug discovery,”Proc. Natl. Acad. Sci. USA, 1992, 89:9367-9371.
Zhang et al. “Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5,”FASEB J., 2000, 14:2589-2600.
Wassberg et al., “Inhibition of Angiogenesis Induces Chromaffin Differentiation and Apoptosis in Neuroblastoma,”Am. J. Pathol., 1999, 154(2):395-403.

Affiliated with

Also associated with

Rating

Endogenous peptide and active subfragments thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Endogenous peptide and active subfragments thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endogenous peptide and active subfragments thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4183988